merger close result
messag provid financi guidanc post merger close
amneal trade vs flattish view confus
ebitda guidanc weak base busi initi guidanc
appear conserv manag note potenti upsid faster expect
synergi addit pipelin product includ manag forecast
adjust estim base earn result compani guidanc
guidanc adj ebitda expect rang adj
ep expect rang provid yearli estim
cost save ramp lead full synergi run-rat within month
synergi
manag expect sequenti quarterli ebitda growth throughout driven
pipelin approv launch late margin expans driven
price initi improv product mix driven new launch cost save
manufactur suppli chain remain commit achiev
revenue/adj ebitda guidanc provid deal announc
pipelin anticip new product launch includ
alreadi launch number character high-valu ftm
opportun believ could upsid opportun manag
provid guidanc launch date-certain good line sight
anda presum commun fda manag
provid color compani launch product throughout year includ
addit opportun product yet disclos respect
gcopaxon gwelchol provid updat time note
gwelchol still sit fda receiv addit recent crl ir
potenti conservat manag may embed conservat
synergi assumpt pipelin guidanc guid cost synergi
run-rat within post-clos realiz greater
half synergi expect realiz late earli manag
hope acceler time synergi exceed target
synergi could prove conserv respect pipelin
manag indic addit launch includ guidanc
could provid potenti upsid addit expect file anda
would consider anda file faster
expect synergi target addit anda file approv launch could result
potenti upsid guidanc
watch item watch item includ suppli constraint relat aggrenox
adrenaclick fda stanc opana er aggrenox compani
suppli constrain due third-parti api manufactur work current
api supplier increas capac attempt secur altern api sourc
adrenaclick compani suppli constrain due contract manufactur
inventori level begin recov manag anticip meet
strong season demand typic seen opana launch opana
er cii settlement agreement ceas shipment
version opana er note marketplac disrupt
begun stabil believ opioid sale remain risk watch futur
action fda take version opana er
result stand-alone report revenu our/consensu
estim impax gener revenu declin y/i
specialti pharma revenu grew y/i gener declin
believ larg attribut suppli shortag adrenaclick gaggrenox
page analyst certif import disclosur
valu amneal use rel valuat ev/ebitda methodolog amneal
trade line gener group averag ev/ebitda believ
appropri given amneal risk/benefit profil maintain neutral rate
risk amneal includ longer expect fda approv timelin higher
expect cost failur success introduc new product market
failur penetr highli generic market obtain approv failur
achiev cost save oper synergi anticip result merger
fda may request remov gener opana er clinic develop risk
inabl compani gain approv fda limit intellectu
properti ip protect control trade secret technolog innov
abil competitor independ develop similar better proprietari inform
techniqu disclos publicli success compet therapi product
becom avail medicar medicaid insur increas effort manag drug
util forecast error determin amneal market opportun
risk includ compani may requir substanti addit fund may financ
futur cash need primarili public privat offer debt financ strateg
collabor may dilut stockhold compani
convers amneal could achiev synergi faster expect compani
respect pipelin could see acceler fda approv timelin key product like
copaxon xyrem approv pend anda result potenti upsid
estim
page analyst certif import disclosur
servic
total servic
revenu
revenu
litigation-rel
acquisition-rel charg
purchas in-process
depreci amort
sale/merg expens
interest dividend incom
reserv ture receiv
sale assets/intang
realiz gain loss invest
unreal gain loss invest
discountinu op net tax
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
